Molecular and Cellular Mechanism in Rhinitis Allergic Patients Treated With GRAZAX® (GT-20)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
The specific clinical trial is a part in which ALK- Abelló will directly work to explore human immunological mechanisms of SIT (observed after GRAZAX treatment).
Condition or disease
The main idea of the project was to address the study of some of the most important inflammatory diseases (psoriasis, rheumatoid arthritis, lupus, rhinitis/asthma… ) with the aim of identifying novel inflammatory markers.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years to 65 Years (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Written informed consent obtained before entering the trial.
Male and female 18-65 years of age.
A clinical history of relevant rhinitis or rhinoconjunctivitis (with/without concurrent asthma) to grass pollen of at least one year prior to trial entry.
Documented positive specific IgE against grass pollen (IgE ≥ Class 2) into the 5 previous years.
Positive Skin Prick Test response (wheal diameter ≥ 3 mm) to Phleum pratense.
Negative pregnancy test for childbearing potential females.
Willing and able to comply with the trial protocol regimen.
Previous treatment by immunotherapy with grass allergen extracts.
A clinical history of symptomatic perennial allergic rhinitis or asthma.
Patients with contraindications for immunotherapy as established by the IT subcommittee of the EAACI or in the Summary of Products Characteristics of GRAZAX®.
Positive pregnancy test (in fertile females).
Being immediate family of the investigator or trial staff.
A mental condition rendering the subject unable to understand the nature, scope and possible consequences of the trial, and/or evidence of an uncooperative attitude.
Unlikely to be able to complete the trial, for any reason, or likely to move, or travel for extended periods of time during the trial period.
Use of an investigational drug within 30 days or 5 half-lives, whichever is longest, prior to screening.